Journal of Analytical & Bioanalytical Techniques
Open Access

Abstract

Spectrofluor TM , also known as Carbon-Fluorine Spectroscopy (CFS TM ) or Fluoro-Raman Spectroscopy (FRS TM ), is a relatively new patented platform technology using a family of various methods and cost-effective devices called PLIRFA TM (Pulsed Laser Isochronic Raman and Fluorescence Apparatus) developed by our team. It was previously demonstrated that Carbon- Fluorine Spectroscopy (CFS TM ), aka Spectro-Fluor TM - a member tool from the PLIRFA TM (Pulsed Laser Isochronic Raman and Fluorine/Fluorescence Apparatus) platform is a green, non-destructive, non-invasive, progressive, reliable and disruptive analytical technology that fits various pharmaceutical and bio-medical applications. The key feature of CFS TM is based on the capability to specifically, sensitively and rapidly detect C-F bond(s) in the fingerprint spectral area of 550-850 cm -1 allowing F-imaging as well as qualitative and quantitative characterization of fluoro organics such as F-drugs and F-biomoleciles in vitro, ex-vivo or in-vivo . More recently, we have applied Spectrofluor TM to characterize nanomaterials (e.g. size determination of ultra-dispersed fluoro-polymers, length determination of fluorinated molecules entrapped into nanoparticles, characterization of house-developed 3D-photonic opal SiO2 nanosponge TM ). Spectrofluor TM may become a gold standard tool for personalized and translational medicine while preserving the environment.

Biography

Farid Menaa, PhD, EMBA and MD candidate, is a young distinguished inter- and multi-disciplinary medical researcher, scientist and technologist. He is also an international consultant for pharmaceutical and nanobiotech companies. He earned his degrees with highest distinctions from prestigious international universities and institutions (e.g. France, USA, Germany, Brazil). As principal investigator in research and clinics, his main current focuses are related to preventive, personalized, translational, integrative and nanomedicine, especially in the areas of oncology, gerontology, regenerative medicine, and pharmaceutical sciences, in order to prevent and implement early diagnosis and efficient therapy. He is an experienced and skilled professional who holds numerous publications (e.g. articles, book chapters, proceedings, pending patents), including in the field of pharmaceutical sciences. He is recipient of several awards.